Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Leronlimab (PRO 140) in Combination With Regorafenib in Patients With CCR5+, Microsatellite Stable (MSS), Metastatic Colorectal Cancer (mCRC)

NCT05730673 is registered in ClinicalTrials.gov with CytoDyn, Inc. as lead sponsor.

NCT NCT05730673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05730673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Leronlimab (PRO 140) in Combination With Regorafenib in Patients With CCR5+, Microsatellite Stable (MSS), Metastatic Colorectal Cancer (mCRC)
Lead sponsor
CytoDyn, Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
September 20, 2022
Completion date
August 10, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ccr5, colorectal cancer, metastatic, microsatellite stable